04.03.18
Dr. Andrew Copestake has been appointed chief commercial officer and executive vice president, Global Business Development, TFS International. Dr. Copestake is an entrepreneurial, commercially focused, senior executive with more than 25 years of experience in the pharmaceutical, biotechnology and CRO industries. Dr. Copestake will be based out of the TFS offices in London.
He most recently served as chief business development officer at Julius Clinical, a CRO based in the Netherlands. Previous roles have included senior leadership positions in business development and general management, including six years as chief executive officer of a Swedish biotechnology company.
“We are delighted to welcome Andrew into our TFS family where he will lead our commercial activities,” said Dr. János Filakovský, chief executive officer. “Andrew has truly global experience and brings with him a deep understanding of our Biopharmaceutical Services industry, in combination with outstanding technical and leadership skills. We are looking forward to him joining to further accelerate our capabilities, service offerings and strengthen our strategic customer relationship strategy.”
He most recently served as chief business development officer at Julius Clinical, a CRO based in the Netherlands. Previous roles have included senior leadership positions in business development and general management, including six years as chief executive officer of a Swedish biotechnology company.
“We are delighted to welcome Andrew into our TFS family where he will lead our commercial activities,” said Dr. János Filakovský, chief executive officer. “Andrew has truly global experience and brings with him a deep understanding of our Biopharmaceutical Services industry, in combination with outstanding technical and leadership skills. We are looking forward to him joining to further accelerate our capabilities, service offerings and strengthen our strategic customer relationship strategy.”